Chronic Kidney Disease
In this Q&A, Ping Liu, PhD, and Pietro Ravani, MD, PhD, answer our questions about the diagnosis and management of chronic kidney disease and discuss how the current definition of CKD does not consider age-related kidney function decline.
To evaluate the existing data on this issue, researchers developed a protocol to comprehensively identify all cohort studies that compared the risk of CKD in coffee drinkers with the risk in non-coffee-drinkers and to combine and analyze the results of these studies.
In this article, James Matera, DO, writes about the benefits of using SGLT2 inhibitors to treat patients with type 2 diabetes, chronic kidney disease, and cardiovascular disease, including how the use of SGLT2 inhibitors can help address racial and ethnic disparities in health care.
In FIGARO-DKD, the primary outcome measure is a composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. Of these outcomes, do you know the predominant outcome? Test your knowledge with our latest pop quiz!